Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

Site 323, Hartsdale

Site 322, Duncansville

Site 324, Wyomissing

Site 338, Mooresville

Site 314, Summerville

Site 344, Myrtle Beach

Site 311, Marietta

Site 316, Dawsonville

Site 332, Jacksonville

Site 340, Miami Gardens

Site 320, Plantation

Site 302, Tampa

Site 315, Tampa

Site 310, Winter Haven

Site 334, Huntsville

Site 341, New Tazewell

Site 343, Cleveland

Site 333, Cincinnati

Site 308, Huber Heights

Site 347, Kettering

Site 325, Valparaiso

Site 304, Evansville

Site 345, Blue Island

Site 336, Bloomington

Site 303, St Louis

Site 321, Overland Park

Site 342, Wichita

Site 329, New Orleans

Site 335, Oklahoma City

Site 330, Dallas

Site 309, San Antonio

Site 318, Austin

Site 331, West Jordan

Site 328, Tucson

Site 306, Las Vegas

Site 312, Eugene

Site 326, Quincy

Site 313, Belvidere

Site 346, Blackwood